Tuesday, 02 January 2024 12:17 GMT

BBNX INVESTOR ALERT: Class Action Lawsuit Filed On Behalf Of Beta Bionics, Inc. Investors Holzer & Holzer, LLC Encourages Investors With Losses To Contact The Firm


(MENAFN- GlobeNewsWire - Nasdaq) ATLANTA, Sept. 08, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics”) (NASDAQ: BBNX). The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts regarding Beta Bionics's iLet Bionic Pancreas insulin pump and the device's safety.

If you purchased Beta Bionics shares between July 30, 2025 and February 24, 2026, and experienced a loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at ..., by toll-free telephone at (888) 508-6832, or by visiting the firm's website at for more information.

The deadline to ask the court to be appointed lead plaintiff in the case is November 3, 2026.

Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, 2023, and 2025, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, , and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.

CONTACT:

Corey D. Holzer, Esq.
(888) 508-6832 (toll-free)
...


MENAFN08092026004107003653ID1111636773



GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.



More Story